Answers are grounded in this paper and cite their sources.
This study aims to describe adult patients with spinal muscular atrophy (SMA) in terms of their demographic and clinical characteristics, treatment patterns and healthcare resource utilization. If possible, it will also explore how adult patients with SMA newly treated with risdiplam (EVRYSDI®) compared with patients who are not receiving disease-modifying therapy (DMT).
No takes yet. Share an insight, caveat, or question.
Guittari et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: